Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind study of clevudine sequential regimens versus entecavir in nucleos(t)ide analogue-experienced chronic hepatitis B
CTR20243350Phase 3Active
- Sponsor
- Beijing Huibaoyuan Pharmaceutical Technology Co., Ltd.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clevudine, entecavir in Chronic Hepatitis B (CHB), sponsored by Beijing Huibaoyuan Pharmaceutical Technology Co., Ltd.. Started Nov 2024; status: active.
02
Drugs
clevudineentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20243350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243350.